Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate CancerRecruiting
NCT07677254N/AUpdated Jul 16, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Neoplasms, Castration-Resistant
United States
A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide TetraxetanRecruiting
NCT07677267N/AUpdated Jul 16, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Neoplasms, Castration-Resistant
United States
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruiting
NCT05467891Phase 2Updated Jul 16, 2026
Sponsor: Oana Danciu
Locoregional Recurrence · Hormone Receptor-positive Breast Cancer · HER2-negative Breast Cancer
United States
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and AlirocumabRecruiting
NCT07543731N/AUpdated Jul 15, 2026
Sponsor: Novartis Pharmaceuticals
Cardiovascular Diseases · Atherosclerotic Cardiovascular Disease · Hypercholesterolemia, Familial
Switzerland
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN LossTerminated
NCT04251533Phase 3Updated Jul 14, 2026
Sponsor: Novartis Pharmaceuticals
Triple Negative Breast Neoplasms
United States, Argentina, Australia, Austria, Brazil +25 more
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate CancerRecruiting
NCT07570979Phase 1Updated Jul 14, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer (mCRPC)
United States, Australia, Japan
A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in SpainNot Yet Recruiting
NCT07598448N/AUpdated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Complement 3 Glomerulopathy
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid LeukemiaTerminated
NCT03874858Phase 2Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myeloid Leukemia
Italy
Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.Recruiting
NCT07243002N/AUpdated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
United Kingdom
Fabhalta Capsules Specified Drug-use SurveyActive Not Recruiting
NCT07156149N/AUpdated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
C3 Glomerulopathy
Japan
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)Not Yet Recruiting
NCT07700056Phase 3Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Pruritus of Unknown Origin
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.Recruiting
NCT04817618Phase 3Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
C3G
United States, Argentina, Belgium, Brazil, Canada +14 more
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGNRecruiting
NCT05755386Phase 3Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
IC-MPGN
United States, Argentina, Brazil, Canada, Czechia +18 more
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)Recruiting
NCT05712200Phase 3Updated Jul 13, 2026
Sponsor: Anthos Therapeutics, Inc.
Atrial Fibrillation (AF)
United States, Argentina, Brazil, Bulgaria, Canada +30 more
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular EventsActive Not Recruiting
NCT05360446Phase 3Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Coronary Artery Disease
United States, Argentina, Australia, Belgium, Brazil +13 more
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate CancerRecruiting
NCT06517719N/AUpdated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Castration Resistant Prostate Cancer
Germany
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL LoweringRecruiting
NCT06865885Phase 4Updated Jul 13, 2026
Sponsor: University of California, San Diego
Drug Interactions · Primary Prevention · Cardiometabolic Syndrome · LDL-Cholersterol Lowering
United States
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsRecruiting
NCT06726148Phase 1, Phase 2Updated Jul 13, 2026
Sponsor: Novartis Pharmaceuticals
Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Extensive-stage Small Cell Lung Cancer
United States, Australia, Canada, China, Czechia +11 more
Up-front CART-BCMA With or Without huCART19 in High-risk Multiple MyelomaActive Not Recruiting
NCT03549442Phase 1Updated Jul 10, 2026
Sponsor: University of Pennsylvania
Multiple Myeloma
United States
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)Recruiting
NCT06711887Phase 3Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Lupus Nephritis
United States, Brazil, China, Colombia, Czechia +11 more
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed FormulationRecruiting
NCT07626281Phase 1Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Inclisiran Formulation
United States
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantTerminated
NCT03439046Phase 3Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
Italy
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionActive Not Recruiting
NCT06004661Phase 2Updated Jul 10, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
United States, France, Germany, Italy, Spain
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung CancersTerminated
NCT06376253Phase 1Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Ovarian Cancer · Lung Cancer
Israel
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular LymphomaCompleted
NCT03568461Phase 2Updated Jul 9, 2026
Sponsor: Novartis Pharmaceuticals
Follicular Lymphoma
United States, Australia, Austria, Belgium, France +7 more

Previous page Next page